Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ramipril

ramipril

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ramipril

24 trials tracked of ramipril: 16 in phase 3 or 4 and 3 with published results. The most-cited published study has 129 citations.

24Trials tracked
16Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 10 Phase 3 6 Phase 2 5 Phase 1 1 Other / NA 2
  1. Phase 4 Nephropathy In Type 2 Diabetes and Cardio-renal Events Completed · 129 cited
  2. Phase 4 Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants Completed · 26 cited
  3. Phase 3 Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI Completed · 16 cited
  4. Phase 4 Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's Completed
  5. Phase 4 Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients Completed
  6. Phase 4 A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension Completed
Show 18 more trials
  1. Phase 4 Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo. Completed
  2. Phase 4 The RAS, Fibrinolysis and Cardiopulmonary Bypass Completed
  3. Phase 4 Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone Completed
  4. Phase 4 Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension Completed
  5. Phase 4 Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus Completed
  6. Phase 3 Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg Completed
  7. Phase 3 Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension Completed
  8. Phase 3 Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF) Completed
  9. Phase 3 Impact of Diabetes on Left Ventricular Remodeling Completed
  10. Phase 3 A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly Completed
  11. Phase 2 Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure Completed
  12. Phase 2 Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis Completed
  13. Phase 2 Testing Ramipril to Prevent Memory Loss in People With Glioblastoma Completed
  14. Phase 2 Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction Completed
  15. Phase 2 Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study Completed
  16. Phase 1 Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers Completed
  17. N/A Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi and PE5i Completed
  18. N/A Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy Completed

Showing the 24 most-cited and recently-updated of 24 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
AI-Based Adjudication of MACE Events Shows High Agreement with Human CEC in MI Trial
Cardiology RCT
AI-Based Adjudication of MACE Events Shows High Agreement with Human CEC in MI Trial AI Can Spot Heart Attacks and Strokes in Medical Records—But Should We Trust It?
This randomized trial compared an AI-based adjudication system (Auto-MACE) to physician CEC adjudication for MACE events in 5,661 patients w…
This new AI tool could speed up medical research by automatically checking medical records for heart problems, saving doctors hundreds of ho…
Apr 23, 2026
Prospective observational study identifies 2,504 potential drug-drug interactions among hospitalized patients with acute coronary syndrome
Drug Pipeline Cohort
Prospective observational study identifies 2,504 potential drug-drug interactions among hospitalized patients with acute coronary syndrome Heart Patients Face Hidden Risks From Common Drug Mixes
This prospective observational cohort study evaluated 371 hospitalized patients with acute coronary syndrome at Assiut University Heart Hosp…
Taking several heart medications at once can create dangerous hidden interactions that increase the risk of treatment failure and hospital s…
Frontiers Apr 19, 2026
Intensive medical treatment failed to reduce major adverse cardiovascular events in women with suspected ANOCA/INOCA over 2.5 years
Cardiology RCT
Intensive medical treatment failed to reduce major adverse cardiovascular events in women with suspected ANOCA/INOCA over 2.5 years Intensive heart medication did not reduce major events in women with suspected ANOCA
This randomized controlled trial enrolled 2,476 women with suspected ANOCA/INOCA across 71 US sites.
Intensive heart medication did not reduce major events in women with suspected ANOCA, finding that aggressive treatment offered no benefit o…
Apr 6, 2026